Abiopharma

FDA approve IRBESARTAN

Biofrontera Notification (BFRI)

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

New Form 8-K - AGIOS PHARMACEUTICALS, INC. Filed: 2025-08-04 AccNo: 0001439222-25-000090 Size: 153 KB Item 7.01: Regulation FD Disclosure

New Form 4 - FULLER H B CO Filed: 2025-08-04 AccNo: 0001225208-25-006967 Size: 18 KB

New Form 4 - FULLER H B CO Filed: 2025-08-04 AccNo: 0001225208-25-006968 Size: 23 KB

New Form D - Nuo Therapeutics, Inc. Filed: 2025-08-04 AccNo: 0001437749-25-024570 Size: 9 KB

New Form 4 - Vir Biotechnology, Inc. Filed: 2025-08-04 AccNo: 0001628280-25-037344 Size: 5 KB

New Form 144 - Spok Holdings, Inc Filed: 2025-08-04 AccNo: 0001949846-25-000337 Size: 4 KB

New Form 144 - Spok Holdings, Inc Filed: 2025-08-04 AccNo: 0001949846-25-000336 Size: 4 KB

New Form D - Phio Pharmaceuticals Corp. Filed: 2025-08-04 AccNo: 0001123292-25-000336 Size: 11 KB

Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

New Form 6-K - NOVO NORDISK A S Filed: 2025-08-04 AccNo: 0001171843-25-004986 Size: 33 KB

RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit